Mark Trusheim

A follow-up survey of clinical and financial health plan leaders uncovers evolving approaches and views on the management of high-cost, curative-intended treatments with one-time administration.

A look at two surveys that reveal payer perspectives regarding current and future management of high-cost durable therapies with one-time administration.